The Trump administration is expected to liberalise research into psychedelic-assisted therapies – and Emyria investors have ...

The last drilling at Golconda took place in 2023, which unlocked some high grade silver zones with hits including 25.9m at ...

Stockhead’s ‘Garimpeiro’ columnist Barry FitzGerald is back in the studio for another instalment of The Explorers Podcast.

Payments company Cuscal's float is likely to be overshadowed by HMC Capital’s DigiCo REIT – to list by Christmas.

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, host Fraser Palamara ...

MA Moelis rates Carnaby a Buy with a high target, while RBC gives FireFly an Outperform rating on its Green Bay project.

The US election failed to deliver extra Chinese stimulus measures companies had been banking on, affecting copper and iron ...

EBR Systems is among ASX healthcare stocks with upcoming catalysts, expecting feedback on a FDA substantive review expected ...

The company's FDA-approved drug Sofdra is the first for the common and embarrassing condition of excessive sweating.

Bitcoin tops record with bets on $100K by December, amid rumours of a nation-state quietly buying Bitcoin and US Bitcoin ...

Investors were clearly feeling jittery on Wednesday, with many trimming positions in riskier assets amid a more uncertain ...

Category four exploration works have been approved allowing C29 (ASX:C29) to carry out a range of tenement-wide activities at ...